Antibody Drug Conjugate Market Review 

The antibody drug conjugate market size was worth USD 1.98 billion in 2021 and is expected to rise from USD 2.31 billion in 2022 to USD 6.81 billion by 2030, with a compound annual growth rate (CAGR) of 16.70% over the forecast period (2022- 2030). They contain monoclonal antibodies that are conjugated with specialized chemical linkers to cytotoxic payloads. ADC has wide applications in prostate cancer, skin cancer, leukemia, pancreas cancer, lymphoma, kidney cancer, solid tumors, ovary cancer, colon cancer, multiple myeloma, lung cancer, breast cancer, glioblastoma, and other cancer types.

Various factors are propelling the global antibody drug conjugate market growth. According to the new MRFR report, such factors include advances in medical technology, growing prevalence of cancer, increasing cases of obesity, surging aging population, and increasing collaboration between biotechnology, biopharmaceuticals, and research institutes, rise in research activities on antibody therapies, research on oncology diseases & advanced drug discoveries. 

On the flip side, a shortage of funds coupled with soaring procedure costs may impede the growth of the antibody drug conjugate market growth during the forecast period. 

Scope of the Report

The report offers an overview of the various parameters of the global antibody drug conjugate market. The market has been segmented based on application, type, technology, end user, and product. It also sheds light on the regional segmentation, market share, size, and current trends.

Market Segmentation

The global antibody drug conjugate market has been segmented based on application, type, technology, end user, and product. 

Based on type, the market is segmented into linker, drug/toxin, monoclonal antibodies, and others.

Based on application, the market is segmented into prostate cancer, skin cancer, leukemia, pancreas cancer, lymphoma, kidney cancer, solid tumors, ovary cancer, colon cancer, multiple myeloma, lung cancer, breast cancer, glioblastoma, and other cancer types. Leukemia is further sub-segmented into acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). 

Based on the product, the market is segmented into adcertis & kadcyla, among others. 

Based on technology, the market is segmented into seattle genetics technology, immunoGen technology, immunomedics technology, among others. 

Based on end-user, the market is segmented into academic research institutes, hospitals, biopharmaceutical companies, specialized cancer centers, biotechnology companies, among others. 

Regional Analysis

Based on the region, the global antibody drug conjugate market report covers the growth opportunities and recent trends across the Americas, Europe, the Asia Pacific (APAC), & the Middle East and Africa (MEA). Among these, the Americas will lead the market over the forecast period. Contribution of nanotechnology to develop antibody drug conjugates (ADC), advances in manufacturing processes, & technological advancements are adding to the global antibody drug conjugate market growth in the region. The United States has the maximum share in the region. 

In Europe, the global antibody drug conjugate market is predicted to possess the second-largest share over the forecast period. Rising prevalence of cancer coupled with rising focus by the government on research and development, are adding to the global antibody drug conjugate market growth in the region. 

In the Asia Pacific region, the global antibody drug conjugate market trend is predicted to expand at a fast pace during the forecast period. Rising cases of cancer, favorable initiatives by the government, coupled with burgeoning consumer awareness, are adding to the antibody drug conjugate market potential in the region. 

In the MEA, the global antibody drug conjugate market is anticipated to have sound growth during the forecast period. 

Key Players

Leading players profiled in the global antibody drug conjugate market report include Astellas Pharma/Agensys (Japan), Oxford BioTherapeutics (US), Concortis Biotherapeutics (US), Heidelberg Pharma (Germany), Millennium Pharmaceuticals (US), ImmunoGen, Inc. (US), Synthon (US), Mersana Therapeutics (US), Progenics Pharmaceuticals (US), Bayer HealthCare (Germany), Antikor (UK), AbbVie Inc. (US), Celldex Therapeutics (US), Roche Holding AG (Switzerland), Pfizer Inc. (US), Immunomedics (US), Agensys, Inc. (US), Genentech (US), and Seattle Genetics (US). Industry players have encompassed different strategies to create a niche in the market, such as acquisitions, new product development, mergers, joint ventures, partnerships, and others. 

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com